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Re: Homeopathy: does a teaspoon of honey help the
medicine go down? Sagar SM. Curr Oncol 2007;
14:126–7.
Sir,
Pointing out the obvious (i.e., that seeking homeo-
pathic treatment for cancer prior to early conventional
diagnosis could be dangerous, and claiming efficacy
for homeopathy’s ultra-highly diluted remedies runs
counter to Avogadro’s hypothesis) does not exoner-
ate Dr. Sagar’s editorial of grossly misrepresenting
the Memory of Water (MoW) hypothesis 1.
This compounds an unwarranted slur not only
on homeopathy, those who practice it, and the mil-
lions around the world who benefit from it, but the
many scientists researching MoW. For his description
of MoW simply ignores recent published research from
the materials, physical, and biochemical sciences 1–6.
In addition, the editorial evinces the usual evangeli-
cal faith in the “gold standard” drug-testing proce-
dure, the double-blind randomized-controlled trial
(DBRCT), and its presumed infallibility at providing
incontestable evidence for or against the efficacy of
homeopathy, or indeed any therapeutic modality 7.
First, Hahnemann never suggested water might
be able to “remember” anything: MoW is a 20th-cen-
tury epithet. Second, MoW has nothing whatever to do
with “subatomic fields”: this would mean invoking
the kind of particle–particle interactions more famil-
iar from high-energy physics experiments! Rather,
MoW is a supramolecular phenomenon involving tril-
lions of water molecules 8, dynamically interrelated
and correlated by well-characterized intermolecular
forces (for example, non-static hydrogen bonding, van
de Waal interactions, and so on), which would no doubt
survive interaction with the –OH groups of lactose.
There is now published literature (some of which I
include here) in reputable journals supporting the kind
of dynamic water “structures” alluded to by MoW 1–5.
Its take-home message is that it is water structure,
not content, that is important 2.
We are still left with the problem of how MoW
might lead to cure of the patient. I would agree that
there is, as yet, much speculation but little research
in this area to repudiate. Assuming it were ever to
get the proper funding, however, such research would
require much closer collaboration between the physi-
cal and biomedical sciences, and is perhaps a timely
reminder of the intellectual parochialism that is a
perennial feature of the latter.
As for the DBRCT, its methodology assumes im-
plicitly that a therapeutic intervention and the con-
text in which it is given may be considered in
complete isolation from one another. Thus, therapeu-
tic modality (in homeopathy, the remedy; in acupunc-
ture, the needle) provides efficacy, while the extended
interview provides context. Ultimately, it is this sepa-
ration of therapy and context that justifies testing
against a “placebo,” one of the least understood con-
cepts in biomedicine.
Of course, all this fits neatly into the biomedical
paradigm and its assertion of a purely molecular basis
to disease. In reality, problems arise for the DBRCT
immediately the separation of therapy and context is
realised for what it is: an arithmetic convenience al-
lowing measurements to be made, statistics to be gath-
ered, and inferences to be drawn. Patient individuality
[something long accepted—in addition to disease/
remedy similarity—in homeopathy and in comple-
mentary and alternative medicine (CAM), but gener-
ally of far lesser importance in conventional
biomedicine] means that therapy and context have to
be seen as intimately correlated. Under these circum-
stances, a fundamentalist approach to the principles
of the DBRCT turns it into a blunt instrument that breaks
this correlation, effectively destroying the very thera-
peutic effect it is trying to investigate 7. It is not sur-
prising, therefore, that over time, DBRCTs of
homeopathy and other CAMs deliver at best equivocal
results or reductions in effect sizes, or both.
Perhaps the DBRCT is not the “gold standard” of
research quality after all, but the scientific equiva-
LETTER TO THE EDITOR
Homeopathy,
fundamentalism, and
the memory of waterLETTER TO THE EDITOR
222
CURRENT ONCOLOGY—VOLUME 14, NUMBER 6
lent of Nelson putting a telescope to his blind eye ...
and far too coarse an experimental procedure. It can
similarly be argued that the DBRCT isn’t always ap-
propriate for investigating conventional medicine ei-
ther 9. For, in real-life circumstances, no therapeutic
intervention—conventional medicine included—is
ever practiced according to the fundamentalist stric-
tures of the DBRCT. Its blindness (methodologic and
sometimes deliberate) to the toxic side effects of cer-
tain drugs might help explain the dangers posed by
some recent high-profile pharmaceuticals—for ex-
ample, Seroxat, Vioxx, statins, and so on. Interest-
ingly, a recent report from the House of Commons
Public Accounts Committee in the United Kingdom
concluded that at least 2.68 million people were
harmed during 2006 by conventional medical inter-
vention, representing a staggering 4.5% of the U.K.
population 10. At least homeopathy isn’t this danger-
ous, and Hippocrates, no doubt, is turning somersaults
in his grave. Not surprisingly therefore, there is a
growing challenge to evidence-based medicine (the
edifice being constructed on DBRCTs) 11 coming from
within conventional medicine itself 12,13.
To conclude, perhaps it is sufficient to recognise
(a) that the current biomedical paradigm does not hold
all the answers to sickness and health; (b) certain
therapeutic modalities like homeopathy, while con-
ventionally incomprehensible, are used, approved,
and trusted by millions of people worldwide; and
(c) the public are not stupid: they are highly unlikely
to visit a homeopath if fixing a broken leg, triple by-
pass surgery, or indeed early cancer diagnosis is re-
quired. They might, however, wish to use appropriate
homeopathic/CAM treatment to help recovery, regard-
less of what the good doctors of physik say about the
plausibility or otherwise of a particular therapy.
Thus, the humane way forward is to increase pa-
tient choice via more rational health care systems in
which CAM therapies such as homeopathy are avail-
able, cost effective, and integrated into primary
healthcare. For it is patients who matter, and they
will choose what is best for them. No one has a mo-
nopoly on truth, and ultimately, all healing, be it ho-
meopathy, witch-doctoring, or even conventional
medicine, begins between two consenting beings.
Perhaps in our saner moments, we should try to re-
member this, because it could go a long way in help-
ing all health practitioners work together toward the
same goal: the best we can do for our patients.
Lionel R. Milgrom BSc MSc PhD CChem FRSC LCH MARH
17, Skardu Road, London  NW2 3ES, United Kingdom
E-mail: lionel.milgrom@hotmail.com
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REPLY FROM DR. STEPHEN M. SAGAR
I agree with Dr. Milgrom that some interesting phe-
nomena have been discovered in the supramolecular
modification of water structure and also in molecular
semiotics. However, the link to clinical effects has not
been established. My romantic rationality yearns for
these effects to have clinical application. What clini-
cian or patient would not want negligible toxicity?
Unfortunately, material science data is being fit-
ted retrospectively to a paradigm of homeopathy that
has not been proven to result in clinical effects (over
and above placebo) in the real world (inductive rea-
soning). Therefore my logical rationality cannot con-
done this. Misinterpretation is pseudoscience.
The practice of homeopathy encourages expec-
tation and the so-called placebo effect—and that’s
fine. However, it is nonsense to utilize expensive
homeopathic preparations without the proof that the
compound itself has an effect in addition to the thera-
peutic relationship or, indeed, the packaging. I sup-
port individualization of therapies, but this is no
excuse for not undertaking a randomized controlledLETTER TO THE EDITOR
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trial, because randomization can be performed after
the individualization decision.
Regarding funding, if the many companies that
profit from the sale of expensive homeopathic rem-
edies were to contribute to research, then the truth
would be revealed. Many of the over-the-counter rem-
edies do not individualize, but claim a blanket cure
for all.
Note that in my editorial, I did not use the meta-
phor “a spoonful of sugar.” A “teaspoon of honey”
leaves open the option that there may be other sub-
stances besides sugar that can result in a therapeutic
effect. (Honey contains more than sugars.) However,
it is the responsibility of the scientist to authenticate
these substances and to prove within the clinical sce-
nario that they contribute more than expectation or
the placebo effect.
I am sure that Hippocrates is somersaulting in his
grave, celebrating the many effective therapies that
allopathic medicine has developed for our patients with
cancer. As a humane clinician and a scientist, I sup-
port any intervention that benefits our patients, but I
do not endorse recommendations that are misleading
and not supported by reasonable and rational evidence.
If homeopathy is to advance, it requires deductive rea-
soning and suitable clinical trials that exclude the pow-
erful effects of expectation alone.
Sincerely,
Stephen M. Sagar MD BSc MB MRCP FRCR FRCP
Juravinski Cancer Centre
699 Concession Street
Hamilton, Ontario  L8V 5C2.
E-mail: stephen.sagar@hrcc.on.ca